During the last session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s traded shares were 0.34 million, with the beta value of the company hitting 1.54. At the end of the trading day, the stock’s price was $8.53, reflecting an intraday loss of -3.29% or -$0.29. The 52-week high for the EYPT share is $30.99, that puts it down -263.31 from that peak though still a striking 19.11% gain since the share price plummeted to a 52-week low of $6.90. The company’s market capitalization is $582.18M, and the average intraday trading volume over the past 10 days was 0.73 million shares, and the average trade volume was 1.00 million shares over the past three months.
EyePoint Pharmaceuticals Inc (EYPT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.08. EYPT has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
EyePoint Pharmaceuticals Inc (EYPT) registered a -3.29% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.29% in intraday trading to $8.53, hitting a weekly high. The stock’s 5-day price performance is 17.33%, and it has moved by 20.14% in 30 days. Based on these gigs, the overall price performance for the year is -65.76%. The short interest in EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) is 10.34 million shares and it means that shorts have 11.39 day(s) to cover.
The consensus price target of analysts on Wall Street is $22, which implies an increase of 61.23% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $22 and $22 respectively. As a result, EYPT is trading at a discount of -157.91% off the target high and -157.91% off the low.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
Statistics show that EyePoint Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. EyePoint Pharmaceuticals Inc (EYPT) shares have gone down -6.88% during the last six months, with a year-to-date growth rate less than the industry average at -17.03% against 16.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 29.57%. While earnings are projected to return -19.37% in 2025, the next five years will return -15.76% per annum.
EYPT Dividends
EyePoint Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
EyePoint Pharmaceuticals Inc insiders own 1.14% of total outstanding shares while institutional holders control 93.79%, with the float percentage being 94.87%. CORMORANT ASSET MANAGEMENT, LP is the largest shareholder of the company, while 207.0 institutions own stock in it. As of 2024-06-30, the company held over 8.32 million shares (or 15.7334% of all shares), a total value of $72.43 million in shares.
The next largest institutional holding, with 5.18 million shares, is of SUVRETTA CAPITAL MANAGEMENT, LLC’s that is approximately 9.7818% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $45.03 million.
Also, the Mutual Funds coming in first place with the largest holdings of EyePoint Pharmaceuticals Inc (EYPT) shares are Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund . Data provided on Oct 31, 2024 indicates that Federated Hermes Kaufmann Fund owns about 2.04 shares. This amounts to just over 2.99 percent of the company’s overall shares, with a $17.39 million market value. The same data shows that the other fund manager holds slightly less at 1.61, or about 2.36% of the stock, which is worth about $13.74 million.
